Fully biodegradable nutraceutical packaging an industry first
An agreement signed between TricorBraun and BioBottles will give nutraceutical companies (and potentially pharmaceutical companies) in the US and Canada access to the industry’s first fully biodegradable packaging option.
American packaging designer and distributor TricorBraun have signed an exclusive agreement with BioBottlesTM to offer their biodegradable bottles to the nutraceutical industry, the first and only bottle of its kind for nutraceutical companies in the US and Canada.
In an effort to expand their current sustainable packaging offerings, the agreement will allow TricorBraun to exclusively offer BioBottles in the US and Canada. Made with proprietary technology, BioBottles offer nutraceutical companies and contract organisations an environmentally responsible alternative at a cost-effective price point, with scope to be utilised in pharmaceutical packaging needs.
“Sustainability matters to our customers and their consumers, and it matters to TricorBraun,” Mark O’Bryan, COO at TricorBraun, stated. “Our exclusive BioBottles agreement in another example of our focused efforts to offer comprehensive sustainable options for our customers. We are thrilled to partner with BioBottles to provide our customers with a solution that helps protect both their products and the planet.”
Manufacturered utilising Plastic IQTM technology, BioBottles and BioCapTM transforms HDPE and PP bottles, caps, scoops, and other items into a material that, when discarded, begins to degrade when exposed to UV, oxygen, and microorganisms. Fungi and bacteria are stimulated into treating the material as a food source and consume and fully degrade the packaging. BioBottles claims to leave behind no microplastics and convert into oxygen, carbon dioxide, and biomass, offering nutraceutical and pharmaceutical companies an industry-first, fully biodegradable packaging solution.
CEO and co-founder of BioBottles James Vanbrocklin commented on the partnership: “TricorBraun shares our dedication and commitment to providing sustainable packaging options for the benefit of the planet... We are excited to partner with a respected industry leader like TricorBraun to deliver this unique yet sustainable alternative for nutraceutical companies, and we look forward to working with TricorBraun to expand into new markets.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance